PURPOSE: To report the 1-year progression of visual impairment on psychophysical tests of visual function in patients with early and intermediate age-related macular degeneration (AMD). DESIGN: Prospective, observational study. PARTICIPANTS: Patients with early and intermediate AMD were enrolled from the existing population at the Duke Eye Center, and healthy age-matched control participants were recruited from family members or friends of the AMD patients and from the Duke Optometry and Comprehensive Eye Clinics. METHODS: Patients and control participants recruited during the baseline study were assessed at both 6 and 12 months after the initial study visit. Measurements of visual function included best-corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), low-luminance deficit (LLD), microperimetry percent-reduced threshold (PRT), microperimetry average threshold (AT), and cone contrast tests (CCTs). MAIN OUTCOME MEASURES: Changes in BCVA, LLVA, LLD, microperimetry PRT, microperimetry AT, and CCT results from baseline to 6 months and to 12 months were assessed. RESULTS: Eighty-five patients completed the 12-month examination (19 control participants, 27 early AMD patients, and 39 intermediate AMD patients). Longitudinal analysis detected significant changes from baseline within each group in microperimetry PRT and AT and in the intermediate AMD group only for BCVA and CCT results (P < 0.05). CONCLUSIONS: Microperimetry and CCT are able to detect functional changes resulting from progression of dry AMD within a period as short as 12 months. These functional markers may be useful end points in future clinical trials that assess the effect of potential treatments for AMD.
PURPOSE: To report the 1-year progression of visual impairment on psychophysical tests of visual function in patients with early and intermediate age-related macular degeneration (AMD). DESIGN: Prospective, observational study. PARTICIPANTS: Patients with early and intermediate AMD were enrolled from the existing population at the Duke Eye Center, and healthy age-matched control participants were recruited from family members or friends of the AMDpatients and from the Duke Optometry and Comprehensive Eye Clinics. METHODS:Patients and control participants recruited during the baseline study were assessed at both 6 and 12 months after the initial study visit. Measurements of visual function included best-corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), low-luminance deficit (LLD), microperimetry percent-reduced threshold (PRT), microperimetry average threshold (AT), and cone contrast tests (CCTs). MAIN OUTCOME MEASURES: Changes in BCVA, LLVA, LLD, microperimetry PRT, microperimetry AT, and CCT results from baseline to 6 months and to 12 months were assessed. RESULTS: Eighty-five patients completed the 12-month examination (19 control participants, 27 early AMDpatients, and 39 intermediate AMDpatients). Longitudinal analysis detected significant changes from baseline within each group in microperimetry PRT and AT and in the intermediate AMD group only for BCVA and CCT results (P < 0.05). CONCLUSIONS: Microperimetry and CCT are able to detect functional changes resulting from progression of dry AMD within a period as short as 12 months. These functional markers may be useful end points in future clinical trials that assess the effect of potential treatments for AMD.
Authors: Sina Farsiu; Stephanie J Chiu; Rachelle V O'Connell; Francisco A Folgar; Eric Yuan; Joseph A Izatt; Cynthia A Toth Journal: Ophthalmology Date: 2013-08-29 Impact factor: 12.079
Authors: Kay Scilley; Gregory R Jackson; Artur V Cideciyan; Maureen G Maguire; Samuel G Jacobson; Cynthia Owsley Journal: Ophthalmology Date: 2002-07 Impact factor: 12.079
Authors: Wan Ling Wong; Xinyi Su; Xiang Li; Chui Ming G Cheung; Ronald Klein; Ching-Yu Cheng; Tien Yin Wong Journal: Lancet Glob Health Date: 2014-01-03 Impact factor: 26.763
Authors: Stefanie G Schuman; Anjum F Koreishi; Sina Farsiu; Sin-ho Jung; Joseph A Izatt; Cynthia A Toth Journal: Ophthalmology Date: 2009-01-22 Impact factor: 12.079
Authors: Kimberly J Cocce; Sandra S Stinnett; Ulrich F O Luhmann; Lejla Vajzovic; Anupama Horne; Stefanie G Schuman; Cynthia A Toth; Scott W Cousins; Eleonora M Lad Journal: Am J Ophthalmol Date: 2018-03-15 Impact factor: 5.258
Authors: Jan H Terheyden; Frank G Holz; Steffen Schmitz-Valckenberg; Anna Lüning; Matthias Schmid; Gary S Rubin; Hannah Dunbar; Adnan Tufail; David P Crabb; Alison Binns; Clara I Sánchez; Carel Hoyng; Philippe Margaron; Nadia Zakaria; Mary Durbin; Ulrich Luhmann; Parisa Zamiri; José Cunha-Vaz; Cecília Martinho; Sergio Leal; Robert P Finger Journal: Trials Date: 2020-07-18 Impact factor: 2.279
Authors: Eleonora M Lad; Vivienne Fang; Michel Tessier; Anna Rautanen; Javier Gayan; Sandra S Stinnett; Ulrich F O Luhmann Journal: Ophthalmol Sci Date: 2022-05-20